← 產業報告目錄

Wearables in Pharma & Biotech Market by Product (Smartwatches, CGMs, Bands, Rings, Patches, Injectors), Therapy (Diabetes, Cardio, Onco, Mental Health), Application (Drug Discovery, Clinical Trials, Medication Adherence), End User - Global Forecasts to 2031

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2026-04-02頁數 401報告編號 HIT10410

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The wearables in pharma & biotech market is projected to reach USD 9.97 billion by 2031 from USD 3.98 billion in 2026, at a CAGR of 20.2%. The market is driven by rapid technological developments in biosensors, miniaturization, and digitization. Increasing global digital connectivity is another significant facilitator of the expanding wearable market. The International Telecommunication Union reported that over 5.4 billion people worldwide were using the internet in 2023. This widespread connectivity is enabling the seamless integration of data from wearable devices into cloud environments. Additionally, the All of Us Research Program has recruited more than 500,000 participants, some of whom are contributing data from wearables, including activity levels, heart rate, and sleep patterns. This reflects the growing role of wearable technology in large-scale biomedical research and precision medicine. This growth is further supported by the increasing adoption of remote patient monitoring (RPM) and digital care solutions. In the US, the Centers for Medicare & Medicaid Services reported a substantial increase in reimbursement claims for remote physiological monitoring services following the expansion of the policy in 2022. This indicates widespread adoption of wearable-derived care among healthcare providers. In addition, developments in the accuracy of sensors and multi-parameter monitoring are allowing wearables to measure clinically significant endpoints beyond basic vital signs. This is expanding the scope of wearables in drug safety and therapeutic studies. “By product, continuous glucose monitors (CGMs) segment to account for largest market share” The product segment is divided into smartwatches, fitness bands, smart rings, continuous glucose monitors (CGMs), patches, wearable injectors, and others. The CGMs segment has a large market share due to the high level of support from clinical guidelines, increasing scope of eligible patients, and the ability of the devices to be used with the most advanced diabetic management systems. The American Diabetes Association recommends the use of CGMs for a broad population of diabetic patients, as per the 2024 Standards of Care, thereby increasing the scope of the market. Furthermore, the availability of reimbursement schemes for hundreds of thousands of patients through the National Health Service has also helped the market expand in the region. In addition, approvals by the Food and Drug Administration for interoperable CGMs used in conjunction with insulin delivery systems have also helped the market expand in the region. The devices also provide up to 288 glucose readings in a day, making them highly valuable in the market . “By end user, pharmaceutical and biotech companies accounted for largest market share in 2025” Pharmaceutical and biotech companies dominated the market for wearables in the pharma & biotech market in terms of market share in 2025. This is mainly attributed to the complexity of clinical trials, where pharmaceutical and biotech companies require wearable technologies for data collection. According to a study by the Tufts Center for the Study of Drug Development, clinical trial protocols currently involve more than 20 endpoints on average, thus increasing the requirement for data collection. Wearable technologies are increasingly being used in this context. Furthermore, large-scale research initiatives, such as the UK Biobank, have successfully used wearable technologies for data collection from over 100,000 individuals, thus highlighting the potential of wearable technologies in pharmaceutical research. Considering this, pharmaceutical and biotech companies are likely to remain a dominant end user in this market . “Asia Pacific to witness highest growth rate during forecast period” The Asia Pacific (APAC) region is experiencing the highest growth rate in the wearables in pharma & biotech market. This growth can be attributed to several factors, including improvements in digital health infrastructure, a rise in clinical research activities, and a significant number of underserved patients. According to the WHO, the combined Western Pacific and Southeast Asia regions contribute a large share to the world's disease burden. It has been mentioned by the International Telecommunication Union that the penetration of the Internet in the APAC region has surpassed 66% to 70% in recent years. Additionally, it has been observed that countries like China and India are emerging as hubs for clinical trials, with thousands of trials already conducted in these regions. Technology is being adopted to enhance the efficiency of these trials. In September 2024, Biobeat announced its expansion into Argentina and Chile through a partnership with Infinity Pharma. The breakdown of primary participants is as given below: • By Company Type - Tier 1: 60%, Tier 2: 30%, and Tier 3: 10% • By Designation - C-level: 30%, Director-level: 50%, and Others: 20% • By Region - North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the World: 10%. Abbott (US), Dexcom, Inc. (US), and Masimo (US) are some of the key players in the wearables in pharma & biotech market. • The study includes an in-depth competitive analysis of these key players in the wearables in pharma & biotech market, with their company profiles, recent developments, and key market strategies. Research Coverage This research report categorizes the wearables in pharma & biotech market by Product (Smartwatches, Fitness Bands, Smart Rings, Continuous Glucose Monitors (CGM), Patches, Wearable Injectors, Others), Therapeutic Area (cardiovascular (atherosclerotic cardiovascular disease (ASCVD) / secondary prevention, heart failure (HFREF and HFPEF), hypertension, atrial fibrillation (AF) / stroke prevention, pulmonary hypertension, structural heart disease / interventional cardiology), oncology (solid tumors, hematologic malignancies), diabetes, mental health & behavioral health, respiratory disorders, lifestyle & wellness improvement, neurology, musculoskeletal disorders / pain management, women’s health & reproductive health, other diseases), Application (drug discovery, clinical trials (phase ii, phase iii, phase iv), medication adherence & behavioral support, chronic disease monitoring, personalized & preventive digital therapeutics), end user (pharmaceutical & biotech companies, healthcare providers & clinicians, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the wearables in pharma & biotech market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the wearables in pharma & biotech market. Competitive analysis of upcoming startups in the market ecosystem is covered in this report. Reasons to Buy this Report The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the wearables in pharma & biotech market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. The report provides insights on the following pointers: • Analysis of key drivers (Shift toward value-based and patient-centric healthcare models, Rising prevalence of chronic diseases requiring continuous patient monitoring, Rapid digitalization of healthcare and expansion of telehealth services) restraints (High implementation and integration costs for healthcare providers, Data privacy and cybersecurity concerns) opportunities (Expansion of remote patient monitoring and home-based care models, Integration of advanced analytics and personalized healthcare) and challenges (Interoperability limitations with existing healthcare IT systems, Low patient adoption and digital literacy barriers) influencing the growth of the wearables in pharma & biotech market • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the wearables in pharma & biotech market • Market Development: Comprehensive information about lucrative markets; the report analyses the wearables in pharma & biotech market across varied regions. • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the wearables in pharma & biotech market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like BD (US), Abbott (US), Masimo (US), DexCom, Inc. (US), Medtronic (Ireland), among others, in the wearables in pharma & biotech market.
目錄 Table of Contents
1 INTRODUCTION 37 1.1 STUDY OBJECTIVES 37 1.2 MARKET DEFINITION 37 1.3 STUDY SCOPE 38 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 38 1.3.2 INCLUSIONS AND EXCLUSIONS 39 1.3.3 YEARS CONSIDERED 40 1.4 CURRENCY CONSIDERED 41 1.5 UNIT CONSIDERED 41 1.6 STAKEHOLDERS 41 2 EXECUTIVE SUMMARY 43 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 43 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 44 2.3 DISRUPTIVE TRENDS SHAPING WEARABLES IN PHARMA & BIOTECH MARKET 45 2.4 HIGH-GROWTH SEGMENTS 46 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 47 3 PREMIUM INSIGHTS 48 3.1 ATTRACTIVE OPPORTUNITIES FOR WEARABLES IN PHARMA & BIOTECH MARKET 48 3.2 NORTH AMERICA WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER AND COUNTRY 49 3.3 WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY 50 4 MARKET OVERVIEW 51 4.1 INTRODUCTION 51 4.2 MARKET DYNAMICS 51 4.2.1 DRIVERS 52 4.2.1.1 Shift toward value-based and patient-centric healthcare models 52 4.2.1.2 Prevalence of chronic diseases requiring continuous patient monitoring 52 4.2.1.3 Rapid digitalization of healthcare and expansion of telehealth services 53 4.2.2 RESTRAINTS 53 4.2.2.1 High implementation and integration costs 53 4.2.2.2 Data privacy and cybersecurity concerns 54 4.2.3 OPPORTUNITIES 54 4.2.3.1 Expansion of remote patient monitoring and home-based care models 54 4.2.3.2 Integration of advanced analytics and personalized healthcare 55 4.2.4 CHALLENGES 55 4.2.4.1 Limited interoperability with existing healthcare IT systems 55 4.2.4.2 Low patient adoption and digital literacy barriers 56 4.3 UNMET NEEDS AND WHITE SPACES 56 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 57 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 57 5 INDUSTRY TRENDS 59 5.1 PORTER’S FIVE FORCES ANALYSIS 59 5.1.1 BARGAINING POWER OF SUPPLIERS (MODERATE) 60 5.1.2 BARGAINING POWER OF BUYERS (MODERATE TO HIGH) 60 5.1.3 THREAT OF SUBSTITUTES (LOW TO MODERATE) 60 5.1.4 THREAT OF NEW ENTRANTS (MODERATE) 61 5.1.5 INTENSITY OF COMPETITIVE RIVALRY (HIGH) 61 5.2 MACROECONOMIC INDICATORS 61 5.2.1 GDP TRENDS AND FORECAST 61 5.2.2 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 62 5.3 SUPPLY CHAIN ANALYSIS 62 5.4 ECOSYSTEM ANALYSIS 63 5.5 PRICING ANALYSIS 65 5.5.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY PRODUCT, 2025 65 5.5.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2025 66 5.6 TRADE ANALYSIS 66 5.6.1 IMPORT DATA (HS CODE 9018) 67 5.6.2 EXPORT DATA (HS CODE 9018) 68 5.7 KEY CONFERENCES AND EVENTS, 2026–2027 68 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 69 5.9 INVESTMENT AND FUNDING SCENARIO 70 5.10 CASE STUDY ANALYSIS 71 5.11 IMPACT OF 2025 US TARIFF 73 5.11.1 KEY TARIFF RATES 73 5.11.2 PRICE IMPACT ANALYSIS 74 5.11.3 IMPACT ON COUNTRIES/REGIONS 74 5.11.3.1 US 74 5.11.3.2 Europe 75 5.11.3.3 Asia Pacific 76 5.11.4 IMPACT ON END-USE INDUSTRIES 76 5.11.4.1 Pharmaceutical & biotech companies 76 5.11.4.2 Healthcare providers & clinicians 76 5.11.4.3 Other end users 77   6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 78 6.1 KEY TECHNOLOGIES 78 6.1.1 ADVANCED BIOSENSING AND MULTI-PARAMETER WEARABLES 78 6.1.2 AI-DRIVEN ANALYTICS AND CLINICAL INTELLIGENCE 78 6.2 COMPLEMENTARY TECHNOLOGIES 79 6.2.1 MOBILE HEALTH AND REMOTE PATIENT MONITORING 79 6.2.2 ANALYTICS AND POPULATION-LEVEL HEALTH DATA INTEGRATION 79 6.3 ADJACENT TECHNOLOGIES 79 6.3.1 INTERNET OF MEDICAL THINGS AND CONNECTED DEVICES 80 6.3.2 CLOUD AND EDGE COMPUTING 80 6.4 TECHNOLOGY/PRODUCT ROADMAP 80 6.5 PATENT ANALYSIS 81 6.5.1 PATENT PUBLICATION TRENDS 81 6.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 82 6.6 FUTURE APPLICATIONS 85 6.6.1 AI-DRIVEN PREDICTIVE MONITORING AND CLINICAL DECISION SUPPORT 85 6.6.2 CLOSED-LOOP THERAPEUTIC AND DRUG DELIVERY SYSTEMS 85 6.6.3 DECENTRALIZED AND HYBRID CLINICAL TRIAL ENABLEMENT 85 6.6.4 CONTINUOUS DISEASE MANAGEMENT AND PREVENTIVE HEALTHCARE 85 6.6.5 ADVANCED BIOSENSING AND NON-INVASIVE DIAGNOSTICS 86 6.6.6 INTEGRATION WITH DIGITAL THERAPEUTICS AND PERSONALIZED MEDICINE 86 6.7 IMPACT OF AI/GEN AI 86 6.7.1 MARKET POTENTIAL OF AI/GEN AI 87 6.7.2 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 88 6.7.2.1 AI-driven continuous glucose monitoring and diabetes management at Dexcom 88 6.7.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 89 6.7.3.1 Wearable data analytics and AI-driven monitoring platforms 89 6.7.3.2 Digital health platforms, integration, and regulatory infrastructure 89 6.7.3.3 Clinical care, remote monitoring, and personalized therapeutics 90 6.7.4 USER READINESS AND IMPACT ASSESSMENT 90 6.7.4.1 User readiness 90 6.7.4.1.1 User A: Hospitals, clinics, and long-term care providers 90 6.7.4.1.2 User B: Pharma and biotech companies 90 6.7.4.2 Impact assessment 91 6.7.4.2.1 User A: Hospitals, clinics, and long-term care providers 91 6.7.4.2.1.1 Implementation 91 6.7.4.2.1.2 Impact 91 6.7.4.2.2 User B: Pharma and biotech companies 91 6.7.4.2.2.1 Implementation 91 6.7.4.2.2.2 Impact 91 7 REGULATORY LANDSCAPE 92 7.1 REGIONAL REGULATIONS AND COMPLIANCE 92 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 7.1.2 INDUSTRY STANDARDS 95 8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 96 8.1 DECISION-MAKING PROCESS 96 8.2 KEY STAKEHOLDERS IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 96 8.2.1 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS 96 8.2.2 BUYING CRITERIA 97 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 98 8.4 UNMET NEEDS FROM END-USE INDUSTRIES 99 8.4.1 UNMET NEEDS 99 8.4.2 END-USER EXPECTATIONS 100 8.5 MARKET PROFITABILITY 100 9 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT 101 9.1 INTRODUCTION 102 9.2 SMARTWATCHES 103 9.2.1 EXPANDING ROLE IN DIGITAL CLINICAL TRIALS AND REMOTE MONITORING 103 9.3 FITNESS BANDS 104 9.3.1 EMPHASIS ON REAL-WORLD EVIDENCE AND PATIENT-CENTRIC TRIAL DESIGNS 104 9.4 SMART RINGS 105 9.4.1 EMERGING CLINICAL-GRADE WEARABLES ENABLING EARLY DISEASE DETECTION AND CONTINUOUS MONITORING 105 9.5 CONTINUOUS GLUCOSE MONITORS 106 9.5.1 TRANSFORMING METABOLIC RESEARCH THROUGH REAL-TIME, HIGH-FREQUENCY DATA 106 9.6 PATCHES 107 9.6.1 CONTINUOUS, CLINICAL-GRADE MONITORING DRIVING ADOPTION IN DECENTRALIZED TRIALS 107 9.7 WEARABLE INJECTORS 109 9.7.1 GROWING DEMAND FOR SELF-ADMINISTRATION OF BIOLOGICS IN CHRONIC DISEASE MANAGEMENT 109 9.8 OTHER PRODUCTS 110 10 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA 111 10.1 INTRODUCTION 112 10.2 CARDIOVASCULAR 112 10.2.1 ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION 114 10.2.1.1 Focus on improving endpoint capture and long-term outcomes monitoring 114 10.2.2 HEART FAILURE 115 10.2.2.1 Continuous physiologic monitoring and AI-enabled decompensation prediction 115 10.2.3 HYPERTENSION 116 10.2.3.1 Cuffless monitoring and AI-driven adherence management enabling precision blood pressure control 116 10.2.4 ATRIAL FIBRILLATION/STROKE PREVENTION 118 10.2.4.1 Rapid expansion of AI-powered arrhythmia detection algorithms and regulatory-cleared wearable ECG technologies 118 10.2.5 PULMONARY HYPERTENSION 119 10.2.5.1 Growing use of wearable-enabled remote monitoring and AI analytics to generate objective, real-world functional endpoints 119 10.2.6 STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY 121 10.2.6.1 Wearable-enabled remote recovery monitoring and procedural optimization supporting precision structural heart care 121 10.3 ONCOLOGY 122 10.3.1 SOLID TUMORS 123 10.3.1.1 BREAST CANCER 125 10.3.1.1.1 Continuous wearable-based survivorship monitoring and decentralized oncology trials driving personalized long-term care models 125 10.3.1.2 LUNG CANCER 126 10.3.1.2.1 Constant respiratory monitoring and decentralized trial adoption 126 10.3.1.3 PROSTATE CANCER 127 10.3.1.3.1 Expansion of decentralized oncology trials and long-term survivorship management 127 10.3.1.4 COLORECTAL CANCER 128 10.3.1.4.1 Increasing adoption of decentralized oncology trials and remote post-surgical monitoring 128 10.3.1.5 BRAIN TUMOR 129 10.3.1.5.1 Remote neurologic surveillance and functional recovery tracking accelerating personalized care 129 10.3.1.6 OTHER SOLID TUMORS 130 10.3.2 HEMATOLOGIC MALIGNANCIES 130 10.3.2.1 LEUKEMIA 132 10.3.2.1.1 Wearable-enabled infection surveillance and treatment resilience monitoring transforming outpatient care 132 10.3.2.2 LYMPHOMA 133 10.3.2.2.1 Shift toward outpatient infusion centers, home-based recovery, and decentralized clinical trials 133 10.3.2.3 MULTIPLE MYELOMA 134 10.3.2.3.1 Real-time toxicity and mobility tracking using wearables in long-term management 134 10.3.2.4 OTHER HEMATOLOGIC MALIGNANCIES 135   10.3.3 DIABETES 136 10.3.3.1 Critical need for long-term, real-world metabolic monitoring 136 10.3.4 MENTAL HEALTH & BEHAVIORAL HEALTH 138 10.3.4.1 Rising global burden of psychiatric disorders 138 10.3.5 RESPIRATORY DISORDERS 139 10.3.5.1 Early exacerbation detection through continuous monitoring reduces hospitalization 139 10.3.6 LIFESTYLE & WELLNESS IMPROVEMENT 140 10.3.6.1 Continuous tracking for lifestyle optimization and preventive health risk management 140 10.3.7 NEUROLOGY 142 10.3.7.1 Wearable-based monitoring of neurological function and digital clinical endpoints in CNS disorders 142 10.3.8 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT 144 10.3.8.1 Wearable-guided functional movement and chronic pain monitoring in musculoskeletal disorders 144 10.3.9 WOMEN'S HEALTH & REPRODUCTIVE HEALTH 145 10.3.9.1 Continuous physiological and reproductive cycle using wearables 145 10.3.10 OTHER DISEASES 146 11 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION 148 11.1 INTRODUCTION 149 11.2 DRUG DISCOVERY 149 11.2.1 RECENT ADVANCES PROMOTE DISCOVERY OF DRUGS THROUGH WEARABLES IN PHARMA & BIOTECH 149 11.3 CLINICAL TRIALS 151 11.3.1 PHASE II 152 11.3.1.1 AI-enabled remote monitoring and adaptive trial designs accelerate adoption 152 11.3.2 PHASE III 153 11.3.2.1 Rapid expansion of decentralized and hybrid global trial models propels growth 153 11.3.3 PHASE IV 155 11.3.3.1 Ability to improve patient engagement and retention in long-duration studies drives market 155 11.4 MEDICATION ADHERENCE & BEHAVIORAL SUPPORT 156 11.4.1 CONNECTED REMINDERS, PASSIVE MONITORING, AND PERSONALIZED NUDGES BOOST ADOPTION 156 11.5 CHRONIC DISEASE MONITORING 158 11.5.1 CONTINUOUS PHYSIOLOGICAL TRACKING AND PROACTIVE INTERVENTION CAPABILITIES INCREASE ADOPTION 158 11.6 PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS 159 11.6.1 BIOMETRIC SENSING AND AI-DRIVEN COACHING RAISE DEMAND FOR WEARABLES 159   12 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER 161 12.1 INTRODUCTION 162 12.2 PHARMACEUTICAL & BIOTECH COMPANIES 162 12.2.1 CLINICAL DIGITIZATION, REAL-WORLD EVIDENCE GENERATION, AND CONNECTED THERAPY MODELS DRIVE MARKET 162 12.3 HEALTHCARE PROVIDERS & CLINICIANS 163 12.3.1 REMOTE PATIENT MONITORING, PREVENTIVE CARE, AND DATA-DRIVEN CLINICAL DECISION SUPPORT BOOST GROWTH 163 12.4 CONTRACT RESEARCH ORGANIZATIONS 165 12.4.1 DECENTRALIZED TRIALS, WEARABLE DATA INTEGRATION, AND FASTER CLINICAL EXECUTION RAISE DEMAND 165 12.5 OTHER END USERS 166 13 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION 168 13.1 INTRODUCTION 169 13.2 NORTH AMERICA 169 13.2.1 US 175 13.2.1.1 High concentration of clinical research activity, clinical trial inefficiencies, and cost pressures to drive market 175 13.2.2 CANADA 180 13.2.2.1 Clinical research participation, public health burden, and digital health adoption to drive market 180 13.3 EUROPE 184 13.3.1 GERMANY 189 13.3.1.1 Expanding clinical trial activity and regulatory leadership to drive market 189 13.3.2 FRANCE 193 13.3.2.1 Regulatory-first approach to healthcare and clinical innovation to drive market 193 13.3.3 UK 197 13.3.3.1 Real-world data integration and decentralized trial innovation to drive market 197 13.3.4 ITALY 201 13.3.4.1 Evolving clinical trial landscape and regulatory decentralization to drive market 201 13.3.5 SPAIN 205 13.3.5.1 Increasing investment in digital health infrastructure to drive market 205 13.3.6 REST OF EUROPE 209 13.4 ASIA PACIFIC 213 13.4.1 CHINA 219 13.4.1.1 Clinical trial expansion and real-world data integration to drive market 219 13.4.2 JAPAN 223 13.4.2.1 Late-stage trial leadership and regulatory precision to drive market 223 13.4.3 INDIA 227 13.4.3.1 High-volume Phase III trial ecosystem and ABDM-driven digital health integration to drive market 227 13.4.4 AUSTRALIA 232 13.4.4.1 Early-phase trial leadership and remote care needs to drive market 232 13.4.5 SOUTH KOREA 236 13.4.5.1 Integrated clinical trial ecosystem and national health data infrastructure to drive market 236 13.4.6 REST OF ASIA PACIFIC 240 13.5 LATIN AMERICA 244 13.5.1 BRAZIL 249 13.5.1.1 Clinical trial leadership and high diabetes burden to drive market 249 13.5.2 MEXICO 253 13.5.2.1 Regulatory reforms and Phase III trial expansion to drive market 253 13.5.3 REST OF LATIN AMERICA 257 13.6 MIDDLE EAST & AFRICA 261 13.6.1 GCC 265 13.6.2 SAUDI ARABIA 269 13.6.2.1 Vision 2030–led digital health transformation to drive market 269 13.6.3 UAE 273 13.6.3.1 Digital health strategy, clinical trial expansion, and high healthcare investment to drive market 273 13.6.4 REST OF GCC 277 13.6.5 SOUTH AFRICA 281 13.6.5.1 Clinical trial leadership and decentralized care models to drive market 281 13.6.6 REST OF MIDDLE EAST & AFRICA 285 14 COMPETITIVE LANDSCAPE 290 14.1 OVERVIEW 290 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 290 14.3 REVENUE ANALYSIS, 2021–2025 292 14.4 MARKET SHARE ANALYSIS, 2025 292 14.5 BRAND/PRODUCT COMPARISON 295 14.6 COMPANY VALUATION AND FINANCIAL METRICS 296 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 297 14.7.1 STARS 297 14.7.2 EMERGING LEADERS 297 14.7.3 PERVASIVE PLAYERS 297 14.7.4 PARTICIPANTS 297 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 299 14.7.5.1 Company footprint 299 14.7.5.2 Region footprint 300 14.7.5.3 Product footprint 301 14.7.5.4 Therapeutic area footprint 302 14.7.5.5 Application footprint 303 14.7.5.6 End user footprint 304 14.8 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025 305 14.8.1 PROGRESSIVE COMPANIES 305 14.8.2 RESPONSIVE COMPANIES 305 14.8.3 DYNAMIC COMPANIES 305 14.8.4 STARTING BLOCKS 305 14.8.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2025 307 14.8.5.1 List of start-ups/SMEs 307 14.8.5.2 Competitive benchmarking of start-ups/SMEs 307 14.9 COMPETITIVE SCENARIO 308 14.9.1 PRODUCT LAUNCHES AND APPROVALS 308 14.9.2 DEALS 309 14.9.3 OTHER DEVELOPMENTS 309 15 COMPANY PROFILES 310 15.1 KEY PLAYERS 310 15.1.1 DEXCOM, INC. 310 15.1.1.1 Business overview 310 15.1.1.2 Products offered 311 15.1.1.3 Recent developments 312 15.1.1.3.1 Product launches and approvals 312 15.1.1.3.2 Deals 312 15.1.1.4 MnM view 313 15.1.1.4.1 Right to win 313 15.1.1.4.2 Strategic choices 313 15.1.1.4.3 Weaknesses and competitive threats 314 15.1.2 ABBOTT 315 15.1.2.1 Business overview 315 15.1.2.2 Products offered 316 15.1.2.3 Recent developments 317 15.1.2.3.1 Product launches and approvals 317 15.1.2.3.2 Deals 318 15.1.2.3.3 Other developments 318 15.1.2.4 MnM view 318 15.1.2.4.1 Right to win 318 15.1.2.4.2 Strategic choices 319 15.1.2.4.3 Weaknesses and competitive threats 319   15.1.3 MASIMO 320 15.1.3.1 Business overview 320 15.1.3.2 Products offered 321 15.1.3.3 Recent developments 322 15.1.3.3.1 Product launches and approvals 322 15.1.3.3.2 Deals 323 15.1.3.4 MnM view 324 15.1.3.4.1 Right to win 324 15.1.3.4.2 Strategic choices 324 15.1.3.4.3 Weaknesses and competitive threats 324 15.1.4 BD 325 15.1.4.1 Business overview 325 15.1.4.2 Products offered 326 15.1.4.3 Recent developments 327 15.1.4.3.1 Product launches and approvals 327 15.1.4.3.2 Deals 327 15.1.4.4 MnM view 328 15.1.4.4.1 Right to win 328 15.1.4.4.2 Strategic choices 328 15.1.4.4.3 Weaknesses and competitive threats 328 15.1.5 APPLE INC. 329 15.1.5.1 Business overview 329 15.1.5.2 Products offered 330 15.1.5.3 Recent developments 331 15.1.5.3.1 Product launches and approvals 331 15.1.5.3.2 Deals 331 15.1.5.4 MnM view 332 15.1.5.4.1 Right to win 332 15.1.5.4.2 Strategic choices 332 15.1.5.4.3 Weaknesses and competitive threats 332 15.1.6 BOSTON SCIENTIFIC CORPORATION 333 15.1.6.1 Business overview 333 15.1.6.2 Products offered 334 15.1.6.3 Recent developments 335 15.1.6.3.1 Deals 335 15.1.7 IRHYTHM TECHNOLOGIES, INC. 336 15.1.7.1 Business overview 336 15.1.7.2 Products offered 337 15.1.7.3 Recent developments 338 15.1.7.3.1 Product launches and approvals 338 15.1.7.3.2 Deals 338   15.1.8 KONINKLIJKE PHILIPS N.V. 339 15.1.8.1 Business overview 339 15.1.8.2 Products offered 340 15.1.8.3 Recent developments 341 15.1.8.3.1 Product launches and approvals 341 15.1.8.3.2 Deals 341 15.1.8.3.3 Other developments 342 15.1.9 MEDTRONIC 343 15.1.9.1 Business overview 343 15.1.9.2 Products offered 344 15.1.9.3 Recent developments 345 15.1.9.3.1 Deals 345 15.1.10 BIOINTELLISENSE, INC. 346 15.1.10.1 Business overview 346 15.1.10.2 Products offered 347 15.1.10.3 Recent developments 347 15.1.10.3.1 Product launches and approvals 347 15.1.10.3.2 Deals 348 15.1.11 F. HOFFMANN-LA ROCHE LTD 349 15.1.11.1 Business overview 349 15.1.11.2 Products offered 350 15.1.11.3 Recent developments 351 15.1.11.3.1 Product launches and approvals 351 15.1.12 GE HEALTHCARE 352 15.1.12.1 Business overview 352 15.1.12.2 Products offered 353 15.1.12.3 Recent developments 354 15.1.12.3.1 Product launches and approvals 354 15.1.12.3.2 Deals 354 15.1.13 BIOBEAT 355 15.1.13.1 Business overview 355 15.1.13.2 Products offered 355 15.1.13.3 Recent developments 356 15.1.13.3.1 Product launches and approvals 356 15.1.13.3.2 Deals 357 15.1.13.3.3 Other developments 357 15.1.14 EMPATICA INC. 358 15.1.14.1 Business overview 358 15.1.14.2 Products offered 359 15.1.14.3 Recent developments 359 15.1.14.3.1 Product launches and approvals 359 15.1.14.3.2 Deals 360 15.1.15 VITALCONNECT 361 15.1.15.1 Business overview 361 15.1.15.2 Products offered 361 15.1.15.3 Recent developments 362 15.1.15.3.1 Deals 362 15.1.15.3.2 Other developments 362 15.1.16 AMETRIS, LLC 363 15.1.16.1 Business overview 363 15.1.16.2 Products offered 363 15.1.16.3 Recent developments 364 15.1.16.3.1 Deals 364 15.1.17 ALIVECOR, INC. 366 15.1.17.1 Business overview 366 15.1.17.2 Products offered 366 15.1.17.3 Recent developments 367 15.1.17.3.1 Product launches and approvals 367 15.1.17.3.2 Deals 368 15.1.18 WITHINGS 369 15.1.18.1 Business overview 369 15.1.18.2 Products offered 370 15.1.18.3 Recent developments 370 15.1.18.3.1 Product launches and approvals 370 15.1.18.3.2 Deals 371 15.1.19 VIVALNK, INC. 372 15.1.19.1 Business overview 372 15.1.19.2 Products offered 372 15.1.19.3 Recent developments 373 15.1.19.3.1 Product launches and approvals 373 15.1.20 MEDIBIOSENSE 374 15.1.20.1 Business overview 374 15.1.20.2 Products offered 374 15.1.20.3 Recent developments 375 15.1.20.3.1 Product launches and approvals 375 15.2 OTHER PLAYERS 376 15.2.1 SIBEL HEALTH, INC. 376 15.2.2 BYTEFLIES 376 15.2.3 STRADOS LABS 377 15.2.4 ONERA TECHNOLOGIES B.V. 377 15.2.5 EPICORE BIOSYSTEMS, INC. 378   16 RESEARCH METHODOLOGY 379 16.1 RESEARCH APPROACH 379 16.1.1 SECONDARY RESEARCH 380 16.1.1.1 Key data from secondary sources 381 16.1.2 PRIMARY RESEARCH 381 16.1.2.1 Primary sources 382 16.1.2.2 Key data from primary sources 383 16.1.2.3 Breakdown of primary interviews 383 16.1.2.4 Insights from primary experts 384 16.2 RESEARCH METHODOLOGY DESIGN 384 16.3 MARKET SIZE ESTIMATION 385 16.4 DATA TRIANGULATION 390 16.5 RESEARCH ASSUMPTIONS 391 16.6 RESEARCH LIMITATIONS 391 16.6.1 METHODOLOGY-RELATED 391 16.6.2 SCOPE-RELATED 391 16.7 RISK ASSESSMENT 392 17 APPENDIX 393 17.1 DISCUSSION GUIDE 393 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 397 17.3 CUSTOMIZATION OPTIONS 399 17.4 RELATED REPORTS 399 17.5 AUTHOR DETAILS 400
圖表清單 List of Tables & Figures
TABLE 1 EXCHANGE RATES FOR CURRENCY CONVERSION 41 TABLE 2 IMPACT OF PORTER’S FIVE FORCES 60 TABLE 3 ROLE OF COMPANIES IN ECOSYSTEM 64 TABLE 4 INDICATIVE PRICES OF WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2025 65 TABLE 5 INDICATIVE PRICES OF WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION, 2025 66 TABLE 6 IMPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2024 (USD MILLION) 67 TABLE 7 EXPORT DATA FOR HS CODE 9018-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2024 (USD MILLION) 68 TABLE 8 KEY CONFERENCES AND EVENTS, 2026–2027 69 TABLE 9 CASE 1: CLINICAL GRADE WEARABLE VITAL SIGNS MONITORING IN NEONATAL & MATERNAL TRIALS 71 TABLE 10 CASE 2: MULTI LEAD WEARABLE ECG MONITORING FOR CARDIOLOGY TRIALS 71 TABLE 11 CASE 3: CONTINUOUS RESPIRATORY MONITORING IN CHRONIC LUNG DISEASE 72 TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 73 TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES 82 TABLE 14 LIST OF PATENTS/PATENT APPLICATIONS 84 TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94 TABLE 19 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95 TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 97 TABLE 21 KEY BUYING CRITERIA, BY END USER 98 TABLE 22 UNMET NEEDS IN WEARABLES IN PHARMA & BIOTECH MARKET 99 TABLE 23 END-USER EXPECTATIONS IN WEARABLES IN PHARMA & BIOTECH MARKET 100 TABLE 24 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 102 TABLE 25 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (THOUSAND UNITS) 102 TABLE 26 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SMARTWATCHES 103 TABLE 27 WEARABLES IN PHARMA & BIOTECH MARKET FOR SMARTWATCHES, BY REGION, 2024–2031 (USD MILLION) 103 TABLE 28 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR FITNESS BANDS 104 TABLE 29 WEARABLES IN PHARMA & BIOTECH MARKET FOR FITNESS BANDS, BY REGION, 2024–2031 (USD MILLION) 105 TABLE 30 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SMART RINGS 105 TABLE 31 WEARABLES IN PHARMA & BIOTECH MARKET FOR SMART RINGS, BY REGION, 2024–2031 (USD MILLION) 106 TABLE 32 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTINUOUS GLUCOSE MONITORS 107 TABLE 33 WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTINUOUS GLUCOSE MONITORS, BY REGION, 2024–2031 (USD MILLION) 107 TABLE 34 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PATCHES 108 TABLE 35 WEARABLES IN PHARMA & BIOTECH MARKET FOR PATCHES, BY REGION, 2024–2031 (USD MILLION) 108 TABLE 36 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR WEARABLE INJECTORS 109 TABLE 37 WEARABLES IN PHARMA & BIOTECH MARKET FOR WEARABLE INJECTORS, BY REGION, 2024–2031 (USD MILLION) 109 TABLE 38 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER PRODUCTS 110 TABLE 39 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2031 (USD MILLION) 110 TABLE 40 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 112 TABLE 41 WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 113 TABLE 42 WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY REGION, 2024–2031 (USD MILLION) 113 TABLE 43 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION 115 TABLE 44 WEARABLES IN PHARMA & BIOTECH MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION, BY REGION, 2024–2031 (USD MILLION) 115 TABLE 45 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEART FAILURE 116 TABLE 46 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEART FAILURE, BY REGION, 2024–2031 (USD MILLION) 116 TABLE 47 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HYPERTENSION 117 TABLE 48 WEARABLES IN PHARMA & BIOTECH MARKET FOR HYPERTENSION, BY REGION, 2024–2031 (USD MILLION) 117 TABLE 49 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR ATRIAL FIBRILLATION/STROKE PREVENTION 118 TABLE 50 WEARABLES IN PHARMA & BIOTECH MARKET FOR ATRIAL FIBRILLATION/ STROKE PREVENTION, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 51 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PULMONARY HYPERTENSION 120 TABLE 52 WEARABLES IN PHARMA & BIOTECH MARKET FOR PULMONARY HYPERTENSION, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 53 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY 121 TABLE 54 WEARABLES IN PHARMA & BIOTECH MARKET FOR STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 55 WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 122 TABLE 56 WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 57 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS 124 TABLE 58 WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 124 TABLE 59 WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 60 WEARABLES IN PHARMA & BIOTECH MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 61 WEARABLES IN PHARMA & BIOTECH MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 62 WEARABLES IN PHARMA & BIOTECH MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 63 WEARABLES IN PHARMA & BIOTECH MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 128 TABLE 64 WEARABLES IN PHARMA & BIOTECH MARKET FOR BRAIN TUMOR, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 65 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER SOLID TUMORS, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 66 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES 131 TABLE 67 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 131 TABLE 68 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 69 WEARABLES IN PHARMA & BIOTECH MARKET FOR LEUKEMIA, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 70 WEARABLES IN PHARMA & BIOTECH MARKET FOR LYMPHOMA, BY REGION, 2024–2031 (USD MILLION) 134 TABLE 71 WEARABLES IN PHARMA & BIOTECH MARKET FOR MULTIPLE MYELOMA, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 72 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER HEMATOLOGIC MALIGNANCIES, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 73 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR DIABETES 137 TABLE 74 WEARABLES IN PHARMA & BIOTECH MARKET FOR DIABETES, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 75 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MENTAL HEALTH & BEHAVIORAL HEALTH 138 TABLE 76 WEARABLES IN PHARMA & BIOTECH MARKET FOR MENTAL HEALTH & BEHAVIORAL HEALTH, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 77 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR RESPIRATORY DISORDERS 140 TABLE 78 WEARABLES IN PHARMA & BIOTECH MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 79 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR LIFESTYLE & WELLNESS IMPROVEMENT 141 TABLE 80 WEARABLES IN PHARMA & BIOTECH MARKET FOR LIFESTYLE & WELLNESS IMPROVEMENT, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 81 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR NEUROLOGY 143 TABLE 82 WEARABLES IN PHARMA & BIOTECH MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 83 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT 144 TABLE 84 WEARABLES IN PHARMA & BIOTECH MARKET FOR MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 85 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR WOMEN'S HEALTH & REPRODUCTIVE HEALTH 146 TABLE 86 WEARABLES IN PHARMA & BIOTECH MARKET FOR WOMEN'S HEALTH & REPRODUCTIVE HEALTH, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 87 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER DISEASES 147 TABLE 88 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER DISEASES, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 89 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 149 TABLE 90 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR DRUG DISCOVERY 150 TABLE 91 WEARABLES IN PHARMA & BIOTECH MARKET FOR DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION) 150 TABLE 92 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS 151 TABLE 93 WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 151 TABLE 94 WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 95 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE II CLINICAL TRIALS 153 TABLE 96 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 97 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE III CLINICAL TRIALS 154 TABLE 98 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION) 154 TABLE 99 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE IV CLINICAL TRIALS 156 TABLE 100 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 101 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR MEDICATION ADHERENCE & BEHAVIORAL SUPPORT 157 TABLE 102 WEARABLES IN PHARMA & BIOTECH MARKET FOR MEDICATION ADHERENCE & BEHAVIORAL SUPPORT, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 103 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CHRONIC DISEASE MONITORING 159 TABLE 104 WEARABLES IN PHARMA & BIOTECH MARKET FOR CHRONIC DISEASE MONITORING, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 105 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS 160 TABLE 106 WEARABLES IN PHARMA & BIOTECH MARKET FOR PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS, BY REGION, 2024–2031 (USD MILLION) 160 TABLE 107 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 162 TABLE 108 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES 163 TABLE 109 WEARABLES IN PHARMA & BIOTECH MARKET FOR PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 110 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR HEALTHCARE PROVIDERS & CLINICIANS 164 TABLE 111 WEARABLES IN PHARMA & BIOTECH MARKET FOR HEALTHCARE PROVIDERS & CLINICIANS, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 112 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTRACT RESEARCH ORGANIZATIONS 165 TABLE 113 WEARABLES IN PHARMA & BIOTECH MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 114 OFFERINGS IN WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER END USERS 166 TABLE 115 WEARABLES IN PHARMA & BIOTECH MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 116 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 117 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 118 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 171 TABLE 119 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 172 TABLE 120 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 172 TABLE 121 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 122 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 123 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 124 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 174 TABLE 125 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 174 TABLE 126 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 174 TABLE 127 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 176 TABLE 128 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 176 TABLE 129 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 130 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 131 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 178 TABLE 132 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 178 TABLE 133 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 179 TABLE 134 US: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 135 US: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 179 TABLE 136 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 180 TABLE 137 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 181 TABLE 138 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 139 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 140 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 141 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 142 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 183 TABLE 143 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 183 TABLE 144 CANADA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 183 TABLE 145 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 146 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 185 TABLE 147 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 185 TABLE 148 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 149 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 150 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 151 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 152 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 188 TABLE 153 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 188 TABLE 154 EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 188 TABLE 155 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 189 TABLE 156 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 190 TABLE 157 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 158 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 159 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 160 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 161 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 192 TABLE 162 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 163 GERMANY: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 192 TABLE 164 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 193 TABLE 165 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 194 TABLE 166 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 194 TABLE 167 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 168 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 169 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 170 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 196 TABLE 171 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 196 TABLE 172 FRANCE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 196 TABLE 173 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 197 TABLE 174 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 198 TABLE 175 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 176 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 177 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 178 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 179 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 200 TABLE 180 UK: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 181 UK: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 200 TABLE 182 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 201 TABLE 183 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 202 TABLE 184 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 185 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 186 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 187 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 188 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 204 TABLE 189 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 190 ITALY: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 204 TABLE 191 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 205 TABLE 192 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 206 TABLE 193 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 194 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 195 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 196 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 197 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 208 TABLE 198 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 199 SPAIN: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 208 TABLE 200 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 209 TABLE 201 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 210 TABLE 202 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 203 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 204 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 205 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 211 TABLE 206 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 212 TABLE 207 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 208 REST OF EUROPE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 212 TABLE 209 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 210 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 215 TABLE 211 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 215 TABLE 212 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 213 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 214 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 215 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 216 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218 TABLE 217 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 218 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 218 TABLE 219 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 219 TABLE 220 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 220 TABLE 221 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 222 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 223 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 224 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 225 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 222 TABLE 226 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 227 CHINA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 222 TABLE 228 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 223 TABLE 229 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 224 TABLE 230 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 224 TABLE 231 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 232 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 233 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 234 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 226 TABLE 235 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 236 JAPAN: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 226 TABLE 237 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 228 TABLE 238 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 228 TABLE 239 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 240 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 241 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 242 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 243 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 231 TABLE 244 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 245 INDIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 231 TABLE 246 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 233 TABLE 247 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 233 TABLE 248 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 249 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 250 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 251 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 252 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 235 TABLE 253 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 254 AUSTRALIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 236 TABLE 255 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 237 TABLE 256 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 237 TABLE 257 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 258 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 259 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 260 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 261 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 239 TABLE 262 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 263 SOUTH KOREA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 240 TABLE 264 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 241 TABLE 265 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 241 TABLE 266 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 267 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 268 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 269 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 270 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 243 TABLE 271 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 272 REST OF ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 244 TABLE 273 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 274 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 245 TABLE 275 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 245 TABLE 276 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 277 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 278 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 279 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 280 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 248 TABLE 281 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 282 LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 248 TABLE 283 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 249 TABLE 284 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 250 TABLE 285 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 286 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 287 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 288 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 289 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 252 TABLE 290 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 291 BRAZIL: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 252 TABLE 292 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 253 TABLE 293 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 254 TABLE 294 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 295 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 296 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 297 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 298 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 256 TABLE 299 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 300 MEXICO: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 256 TABLE 301 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 257 TABLE 302 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 258 TABLE 303 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 304 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 305 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 306 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 307 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 260 TABLE 308 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 309 REST OF LATIN AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 260 TABLE 310 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 261 TABLE 311 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 262 TABLE 312 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 262 TABLE 313 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 314 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 315 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 316 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 317 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 264 TABLE 318 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 319 MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 265 TABLE 320 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 321 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 266 TABLE 322 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 266 TABLE 323 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 324 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 325 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 326 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 327 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 268 TABLE 328 GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 329 GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 269 TABLE 330 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 270 TABLE 331 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 270 TABLE 332 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 333 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 334 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 335 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 336 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 272 TABLE 337 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 338 SAUDI ARABIA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 273 TABLE 339 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 274 TABLE 340 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 274 TABLE 341 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 342 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 343 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 344 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 345 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 276 TABLE 346 UAE: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 347 UAE: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 277 TABLE 348 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 278 TABLE 349 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 278 TABLE 350 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 351 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 352 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 353 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 354 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 280 TABLE 355 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 356 REST OF GCC: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 281 TABLE 357 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 282 TABLE 358 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 282 TABLE 359 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 360 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 361 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 362 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 363 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 284 TABLE 364 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 365 SOUTH AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 285 TABLE 366 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 286 TABLE 367 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 286 TABLE 368 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CARDIOVASCULAR, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 369 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 370 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 371 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 372 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 288 TABLE 373 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET FOR CLINICAL TRIALS, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 374 REST OF MIDDLE EAST & AFRICA: WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER, 2024–2031 (USD MILLION) 289 TABLE 375 STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLES IN PHARMA & BIOTECH MARKET, 2023–2026 290 TABLE 376 WEARABLES IN PHARMA & BIOTECH MARKET: DEGREE OF COMPETITION 293 TABLE 377 REGION FOOTPRINT 300 TABLE 378 PRODUCT FOOTPRINT 301 TABLE 379 THERAPEUTIC AREA FOOTPRINT 302 TABLE 380 APPLICATION FOOTPRINT 303 TABLE 381 END USER FOOTPRINT 304 TABLE 382 LIST OF START-UPS/SMES 307 TABLE 383 COMPETITIVE BENCHMARKING OF START-UPS/SMES 307 TABLE 384 WEARABLES IN PHARMA & BIOTECH MARKET: PRODUCT LAUNCHES AND APPROVALS, 2023–2026 308 TABLE 385 WEARABLES IN PHARMA & BIOTECH MARKET: DEALS, 2023–2026 309 TABLE 386 WEARABLES IN PHARMA & BIOTECH MARKET: OTHER DEVELOPMENTS, 2023–2026 309 TABLE 387 DEXCOM, INC.: COMPANY OVERVIEW 310 TABLE 388 DEXCOM, INC.: PRODUCTS OFFERED 311 TABLE 389 DEXCOM, INC.: PRODUCT LAUNCHES AND APPROVALS 312 TABLE 390 DEXCOM, INC.: DEALS 312 TABLE 391 ABBOTT: COMPANY OVERVIEW 315 TABLE 392 ABBOTT: PRODUCTS OFFERED 316 TABLE 393 ABBOTT: PRODUCT LAUNCHES AND APPROVALS 317 TABLE 394 ABBOTT: DEALS 318 TABLE 395 ABBOTT: OTHER DEVELOPMENTS 318 TABLE 396 MASIMO: COMPANY OVERVIEW 320 TABLE 397 MASIMO: PRODUCTS OFFERED 321 TABLE 398 MASIMO: PRODUCT LAUNCHES AND APPROVALS 322 TABLE 399 MASIMO: DEALS 323 TABLE 400 BD: COMPANY OVERVIEW 325 TABLE 401 BD: PRODUCTS OFFERED 326 TABLE 402 BD: PRODUCT LAUNCHES AND APPROVALS 327 TABLE 403 BD: DEALS 327 TABLE 404 APPLE INC.: COMPANY OVERVIEW 329 TABLE 405 APPLE INC.: PRODUCTS OFFERED 330 TABLE 406 APPLE INC.: PRODUCT LAUNCHES AND APPROVALS 331 TABLE 407 APPLE INC.: DEALS 331 TABLE 408 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 333 TABLE 409 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 334 TABLE 410 BOSTON SCIENTIFIC CORPORATION: DEALS 335 TABLE 411 IRHYTHM TECHNOLOGIES, INC.: COMPANY OVERVIEW 336 TABLE 412 IRHYTHM TECHNOLOGIES, INC.: PRODUCTS OFFERED 337 TABLE 413 IRHYTHM TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS 338 TABLE 414 IRHYTHM TECHNOLOGIES, INC.: DEALS 338 TABLE 415 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 339 TABLE 416 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 340 TABLE 417 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES AND APPROVALS 341 TABLE 418 KONINKLIJKE PHILIPS N.V.: DEALS 341 TABLE 419 KONINKLIJKE PHILIPS N.V.: OTHER DEVELOPMENTS 342 TABLE 420 MEDTRONIC: COMPANY OVERVIEW 343 TABLE 421 MEDTRONIC: PRODUCTS OFFERED 344 TABLE 422 MEDTRONIC: DEALS 345 TABLE 423 BIOINTELLISENSE, INC.: COMPANY OVERVIEW 346 TABLE 424 BIOINTELLISENSE, INC.: PRODUCTS OFFERED 347 TABLE 425 BIOINTELLISENSE, INC.: PRODUCT LAUNCHES AND APPROVALS 347 TABLE 426 BIOINTELLISENSE, INC.: DEALS 348 TABLE 427 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 349 TABLE 428 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 350 TABLE 429 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS 351 TABLE 430 GE HEALTHCARE: COMPANY OVERVIEW 352 TABLE 431 GE HEALTHCARE: PRODUCTS OFFERED 353 TABLE 432 GE HEALTHCARE: PRODUCT LAUNCHES AND APPROVALS 354 TABLE 433 GE HEALTHCARE: DEALS 354 TABLE 434 BIOBEAT: COMPANY OVERVIEW 355 TABLE 435 BIOBEAT: PRODUCTS OFFERED 355 TABLE 436 BIOBEAT: PRODUCT LAUNCHES AND APPROVALS 356 TABLE 437 BIOBEAT: DEALS 357 TABLE 438 BIOBEAT: OTHER DEVELOPMENTS 357 TABLE 439 EMPATICA INC.: COMPANY OVERVIEW 358 TABLE 440 EMPATICA INC.: PRODUCTS OFFERED 359 TABLE 441 EMPATICA INC.: PRODUCT LAUNCHES AND APPROVALS 359 TABLE 442 EMPATICA INC.: DEALS 360 TABLE 443 VITALCONNECT: COMPANY OVERVIEW 361 TABLE 444 VITALCONNECT: PRODUCTS OFFERED 361 TABLE 445 VITALCONNECT: DEALS 362 TABLE 446 VITALCONNECT: OTHER DEVELOPMENTS 362 TABLE 447 AMETRIS, LLC: COMPANY OVERVIEW 363 TABLE 448 AMETRIS, LLC: PRODUCTS OFFERED 363 TABLE 449 AMETRIS, LLC: DEALS 364 TABLE 450 ALIVECOR, INC.: COMPANY OVERVIEW 366 TABLE 451 ALIVECOR, INC.: PRODUCTS OFFERED 366 TABLE 452 ALIVECOR, INC.: PRODUCT LAUNCHES AND APPROVALS 367 TABLE 453 ALIVECOR, INC.: DEALS 368 TABLE 454 WITHINGS: COMPANY OVERVIEW 369 TABLE 455 WITHINGS: PRODUCTS OFFERED 370 TABLE 456 WITHINGS: PRODUCT LAUNCHES AND APPROVALS 370 TABLE 457 WITHINGS: DEALS 371 TABLE 458 VIVALNK, INC.: COMPANY OVERVIEW 372 TABLE 459 VIVALNK, INC.: PRODUCTS OFFERED 372 TABLE 460 VIVALNK, INC.: PRODUCT LAUNCHES AND APPROVALS 373 TABLE 461 MEDIBIOSENSE: COMPANY OVERVIEW 374 TABLE 462 MEDIBIOSENSE: PRODUCTS OFFERED 374 TABLE 463 MEDIBIOSENSE: PRODUCT LAUNCHES AND APPROVALS 375 TABLE 464 SIBEL HEALTH, INC.: COMPANY OVERVIEW 376 TABLE 465 BYTEFLIES: COMPANY OVERVIEW 376 TABLE 466 STRADOS LABS: COMPANY OVERVIEW 377 TABLE 467 ONERA TECHNOLOGIES B.V.: COMPANY OVERVIEW 377 TABLE 468 EPICORE BIOSYSTEMS, INC.: COMPANY OVERVIEW 378 FIGURE 1 MARKET SCENARIO 43 FIGURE 2 GLOBAL WEARABLES IN PHARMA & BIOTECH MARKET, 2024–2031 44 FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLES IN PHARMA & BIOTECH MARKET 44 FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF WEARABLES IN PHARMA & BIOTECH MARKET 45 FIGURE 5 HIGH-GROWTH SEGMENTS IN WEARABLES IN PHARMA & BIOTECH MARKET 46 FIGURE 6 ASIA PACIFIC TO BE FASTEST-GROWING REGION DURING FORECAST PERIOD 47 FIGURE 7 EXPANSION OF DECENTRALIZED AND REMOTE PATIENT-CENTRIC TRIALS TO DRIVE MARKET 48 FIGURE 8 PHARMACEUTICAL & BIOTECH COMPANIES AND US ACCOUNTED FOR LARGEST SHARES IN 2025 49 FIGURE 9 INDIA TO EXHIBIT FASTEST GROWTH DURING FORECAST PERIOD 50 FIGURE 10 PORTER’S FIVE FORCES ANALYSIS 59 FIGURE 11 SUPPLY CHAIN ANALYSIS 63 FIGURE 12 ECOSYSTEM ANALYSIS 64 FIGURE 13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 70 FIGURE 15 PATENT PUBLICATION TRENDS, 2015–2026 82 FIGURE 16 JURISDICTION AND TOP APPLICANT ANALYSIS 82 FIGURE 17 PATENT ANALYSIS 83 FIGURE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 97 FIGURE 19 KEY BUYING CRITERIA, BY END USER 98 FIGURE 20 NORTH AMERICA: WEARABLES IN PHARMA & BIOTECH MARKET SNAPSHOT 170 FIGURE 21 ASIA PACIFIC: WEARABLES IN PHARMA & BIOTECH MARKET SNAPSHOT 214 FIGURE 22 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 292 FIGURE 23 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 293 FIGURE 24 BRAND/PRODUCT COMPARISON 295 FIGURE 25 FINANCIAL METRICS (EV/EBITDA) 296 FIGURE 26 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 296 FIGURE 27 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 298 FIGURE 28 COMPANY FOOTPRINT 299 FIGURE 29 COMPANY EVALUATION MATRIX (START-UPS/SMES), 2025 306 FIGURE 30 DEXCOM, INC.: COMPANY SNAPSHOT 311 FIGURE 31 ABBOTT: COMPANY SNAPSHOT 316 FIGURE 32 MASIMO: COMPANY SNAPSHOT 321 FIGURE 33 BD: COMPANY SNAPSHOT 326 FIGURE 34 APPLE INC.: COMPANY SNAPSHOT 330 FIGURE 35 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 334 FIGURE 36 IRHYTHM TECHNOLOGIES, INC.: COMPANY SNAPSHOT 337 FIGURE 37 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT 340 FIGURE 38 MEDTRONIC: COMPANY SNAPSHOT 344 FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT 350 FIGURE 40 GE HEALTHCARE: COMPANY SNAPSHOT 353 FIGURE 41 RESEARCH DESIGN 379 FIGURE 42 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 385 FIGURE 43 BOTTOM-UP APPROACH 386 FIGURE 44 TOP-DOWN APPROACH 386 FIGURE 45 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 388 FIGURE 46 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 388 FIGURE 47 DATA TRIANGULATION 390

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們